research Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Monotherapy for Alopecia Areata: A Systematic Review and Network Meta-Analysis
Intralesional corticosteroids work best for mild alopecia areata, and DPCP works best for moderate to severe cases.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Serum Levels of Transforming Growth Factor Beta1 (TGF β1) in Patients with Alopecia Areata.
People with severe Alopecia Areata have higher levels of TGF-β1, which may play a role in the condition.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research A description of alopecia areata in European patients based on real-world survey data: physician-reported characterization of severity and associated treatment utilization
More effective treatments are needed for severe alopecia areata.
research Effects of Topical Cyclosporin-A in the Treatment of Alopecia Areata
Topical cyclosporin-A is recommended for severe alopecia areata.
research Photochemotherapy and Alopecia Areata
Some people with severe hair loss saw hair regrowth after a specific light and drug treatment.
research Deficient and/or insufficient serum 25 hydroxy vitamin D in patients with alopecia areata: is it a fact or a fiction?
Low vitamin D levels might indicate more severe hair loss in alopecia areata patients.
research Treatment-Resistant Alopecia Areata
Combining 5% minoxidil and 0.5% anthralin can help regrow hair in some severe alopecia areata patients.
research Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin
Using minoxidil and anthralin together can improve hair regrowth in severe alopecia areata patients who didn't respond to individual treatments.
research Pharmacotherapy of alopecia areata
JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
research Complete Blood Collection-based Systemic Inflammation Biomarkers as a Severity Biomarker in Alopecia Areata: A Cross-sectional Study
Higher inflammation markers are linked to more severe alopecia areata.
research Patient-Reported Psychosocial Burdens and Quality of Life and Work Productivity Impacts Among Patients with Clinically Distinct Alopecia Areata Severity Profiles
Alopecia areata negatively impacts quality of life and work, even with moderate hair loss.
research Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy
Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research Consensus Document on the Clinical Management of Alopecia Areata: Recommendations from the Spanish Hair Research Group of the Spanish Academy of Dermatology and Venerology)
JAK inhibitors are recommended for severe alopecia areata if corticosteroids fail.
research Demographic Features, Clinical Factors and Severity of Disease among Patients with Alopecia Areata
More lesions mean more severe alopecia areata.
research INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
research Evaluation of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, CRP and ESR with disease severity in patients with alopecia areata
Higher MPV and CRP levels may indicate more severe alopecia areata.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Supplementary Material for: Monotherapy for Alopecia Areata: A Systematic Review and Network Meta-Analysis
Intralesional corticosteroids are best for mild alopecia areata, and DPCP is best for severe cases.
research Chemokine C-C Motif Ligand 7 (CCL7), a Biomarker of Atherosclerosis, Is Associated with the Severity of Alopecia Areata: A Preliminary Study
Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research 008 Stratifying alopecia areata systemic treatments: Tailored approaches to disease severity
Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Psychosocial and mental impact of alopecia areata: Analysis of the Danish Skin Cohort
Alopecia areata significantly affects mental health, especially in women and those with severe cases.
research Janus kinase inhibitors: An innovative treatment for alopecia areata
New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
research Risk factors for the development of and outcomes after diagnosis of autoimmune alopecia areata in patients with inflammatory bowel diseases
IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.